Summit Therapeutics Inc
Research Summit Therapeutics Inc (SMMT) on Bullrun: market cap USD 10.60B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSMMT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.60B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 215.70M
- Free cash flow-USD 142.03M
Valuation Snapshot
latest market cap is USD 10.60B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 1.08B | -USD 323.59M | n/a | -1.44 | USD 225.27M | USD 20.89M | USD 658.86M |
| FY2024 | USD 0 | -USD 221.32M | -USD 142.25M | n/a | -0.31 | USD 104.86M | USD 7.22M | USD 388.75M |
| FY2023 | USD 0 | -USD 614.93M | -USD 76.89M | n/a | -0.99 | USD 71.43M | USD 106.10M | USD 77.69M |
| FY2022 | USD 705.00K | -USD 78.78M | -USD 42.21M | n/a | -0.41 | USD 348.61M | USD 27.32M | USD 126.65M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 10.60B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 13.56B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 13.16B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.83B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 855.62M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 263.73M | n/a | n/a | n/a |
About Summit Therapeutics Inc
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Summit Therapeutics Inc's market cap?
Summit Therapeutics Inc's market capitalization is USD 10.60B.
What does Summit Therapeutics Inc do?
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).